{"id":"mopv2-at-6-and-8-weeks-of-age","safety":{"commonSideEffects":[{"rate":null,"effect":"Vaccine virus shedding in stool"},{"rate":null,"effect":"Mild gastrointestinal symptoms"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Vaccine-derived poliovirus (VDPV) in rare cases"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"mOPV2 (monovalent oral polio vaccine type 2) contains a weakened live poliovirus type 2 that replicates in the intestinal tract, triggering both mucosal and systemic immune responses. This generates antibodies and cellular immunity against poliovirus type 2, providing protection against infection and disease. The vaccine is administered orally and has been used in global polio eradication campaigns.","oneSentence":"mOPV2 is a live attenuated oral polio vaccine that stimulates immune responses against poliovirus type 2 to prevent poliomyelitis infection.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:55:52.772Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of poliomyelitis caused by poliovirus type 2 in infants at 6 and 8 weeks of age"}]},"trialDetails":[{"nctId":"NCT02643368","phase":"PHASE4","title":"Immunogenicity of Monovalent Type 2 Oral Poliovirus Vaccine","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2015-12","conditions":"Poliomyelitis","enrollment":760},{"nctId":"NCT01831050","phase":"PHASE4","title":"Safety and Immunogenicity of 1 or 2 Doses of IPV in Latin American Infants Primed With Bivalent OPV Vaccine","status":"COMPLETED","sponsor":"Fidec Corporation","startDate":"2013-05","conditions":"Poliomyelitis","enrollment":1420}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"mOPV2 at 6 and 8 weeks of age","genericName":"mOPV2 at 6 and 8 weeks of age","companyName":"Centers for Disease Control and Prevention","companyId":"centers-for-disease-control-and-prevention","modality":"Biologic","firstApprovalDate":"","aiSummary":"mOPV2 is a live attenuated oral polio vaccine that stimulates immune responses against poliovirus type 2 to prevent poliomyelitis infection. Used for Prevention of poliomyelitis caused by poliovirus type 2 in infants at 6 and 8 weeks of age.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}